ALEXANDRA DEANGELIS: Open Payments
NPI 1023741071 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$907 in 41 payments from 14 companies in 2025. Trend: 2023 $498 · 2024 $1,555 · 2025 $907
Food & beverage: $862Education: $45
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 6 | $161 |
| AstraZeneca Pharmaceuticals LP | 8 | $149 |
| Novo Nordisk Inc | 5 | $119 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $96 |
| PFIZER INC. | 4 | $80 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $71 |
| Kowa Pharmaceuticals America, Inc. | 2 | $45 |
| Exact Sciences Corporation | 2 | $38 |
| ABBVIE INC. | 1 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
Products named: JARDIANCE, AIRSUPRA, XIFAXAN, Ozempic, PREVNAR 20, MOUNJARO, BREZTRI, ZORYVE.
Industry payments across CT — which companies pay providers there.
